WallStSmart

Lineage, Inc. Common Stock (LINE)vsRithm Capital Corp. (RITM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 26% more annual revenue ($5.36B vs $4.24B). RITM leads profitability with a 17.0% profit margin vs -2.7%. RITM earns a higher WallStSmart Score of 69/100 (B-).

LINE

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

RITM

Strong Buy

69

out of 100

Grade: B-

Growth: 10.0Profit: 6.0Value: 8.3Quality: 3.5
Piotroski: 2/9Altman Z: 0.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

RITMUndervalued (+83.6%)

Margin of Safety

+83.6%

Fair Value

$65.11

Current Price

$9.13

$55.98 discount

UndervaluedFair: $65.11Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

RITM4 strengths · Avg: 10.0/10
P/E RatioValuation
8.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
64.6%10/10

Revenue surging 64.6% year-over-year

EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

RITM3 concerns · Avg: 2.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

Debt/EquityHealth
4.621/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : RITM

The strongest argument for RITM centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 13.2%. Revenue growth of 64.6% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : RITM

The primary concerns for RITM are Piotroski F-Score, Altman Z-Score, Debt/Equity. Debt-to-equity of 4.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while RITM is a growth play — different risk/reward profiles.

RITM is growing revenue faster at 64.6% — sustainability is the question.

RITM generates stronger free cash flow (254M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RITM scores higher overall (69/100 vs 34/100), backed by strong 17.0% margins and 64.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.

Visit Website →

Rithm Capital Corp.

REAL ESTATE · REIT - MORTGAGE · USA

Rhythm Capital Corp. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?